Questions? +1 (202) 540-8337 Login
Trusted News Since 1995
A service for medical industry professionals · Tuesday, October 16, 2018 · 465,244,684 Articles · 3+ Million Readers

Biologics Market Growth Is 66% Faster Than Pharma

Global Biologics Market Segments

Global Biologics Market Segments

LONDON, GREATER LONDON, UK, April 18, 2018 /EINPresswire.com/ -- The global market for biologics is growing at 9.6% year on year, while the pharmaceutical drugs market is achieving only 5.8% a year, a report from The Business Research Company shows. A significant driver of this increase in biologics' sales growth will be the over 1000 new biologics currently under development. This will lead to an expected multiplication of the 2017 approval rate of 12 biologics in the USA, 10 in the European Union and 7 in Japan. The global market for biologics is now almost a quarter as big as that for pharmaceutical drugs and it accounts for 3% of global healthcare expenditure.

Biologics are very large complex molecules manufactured in living systems such as microorganisms, animal cells or plant cells. They are produced using recombinant DNA technology and are composed of sugars, proteins, nucleic acids or a combination of these substances.

Monoclonal antibodies (mAbs) are the largest segment of the biologics market, worth 42.5% of the global total, followed by therapeutic proteins at 36% and vaccines at 21%. All three segments are growing at over 9% year on year.

The anti-cancer therapeutic area of the monoclonal antibodies segment is the largest subsegment, worth $46.97 billion, followed by the metabolic disorders area of the therapeutic proteins segment and the anti-infective therapeutic area of the vaccines segment.

North America's biologics market is the largest, worth nearly 40% of the total, followed by Western Europe at 23% and the Asia Pacific at 16%. By country, the market in the USA dominates, being worth $61.1 billion, nearly seven times as much as the second-largest, Japan. The largest single segment is the US market for monoclonal antibodies, which is worth $27.1 billion.

The biologics market is quite concentrated: the top five competitors' shares amounted to 59% of the total in 2017. Johnson & Johnson, Hoffman-La Roche, and Bristol-Myers Squibb are the three largest players.

Where to Learn More
Read the Biologics Market Report from The Business Research Company for information on the following:
Markets Covered: Biologics, Monoclonal Antibodies, Therapeutic Proteins and Vaccines
Biologics Companies Mentioned: Amgen, AbbVie, Johnson & Johnson, Bristol-Meyers Squib, Pfizer, Eli Lilly and Company, F. Hoffmann-La Roche, Merck & Co., GlaxoSmithKline, Sanofi
Countries: India, China, Japan, Australia, UK, Germany, France, Italy, Spain, Russia, USA, Brazil
Regions: North America, South America, Western Europe, Eastern Europe, Africa, Middle East, Asia Pacific
Time Series: Five years historic and forecast.
Data: Ratios of market size and growth to related markets, population, GDP, Biologics Indicators Comparison.
Data Segmentations: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report are sourced using endnotes.

Oliver Guirdham
The Business Research Company
+44 207 1930 708
email us here

Powered by EIN Presswire